Form 4: Director Sells LGND Shares Under 10b5-1 Plan

A director of Ligand Pharmaceuticals Inc. sold 467 shares of common stock on February 2, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• John W. Kozarich, a Director of Ligand Pharmaceuticals Inc. (LGND), reported the sale of common stock.
• The transactions occurred on February 2, 2026.
• A total of 467 shares were sold across multiple transactions at prices ranging from $191.00 to $197.195 per share.
• These sales were executed pursuant to a written trading plan adopted by Mr. Kozarich on March 7, 2025, in accordance with Rule 10b5-1.
• Following these transactions, Mr. Kozarich beneficially owns 43,187 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral. While it's an insider sale, the pre-arranged 10b5-1 plan mitigates concerns about immediate negative sentiment, suggesting personal financial planning rather than a reaction to new company developments.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction for personal financial management rather than a reaction to new company developments.

Negatives

• A director reducing their stake, even under a 10b5-1 plan, can sometimes be perceived as a slight reduction in insider alignment, though the context of the plan mitigates this concern.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice for corporate insiders to manage their personal finances, diversify portfolios, or address tax planning needs. Such pre-scheduled transactions are generally viewed as less indicative of management's immediate sentiment about the company's prospects compared to unscheduled, open-market sales.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in a director's direct ownership, which is generally not considered a significant event given the pre-planned nature and relatively small volume.

Key Dates

Recommendation

The sale by a director, John W. Kozarich, was executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025. Such planned sales are typically for personal financial management, diversification, or tax purposes and do not necessarily reflect a change in the director's outlook on the company's future performance. The volume of shares sold (467 shares) is relatively small compared to the remaining beneficial ownership (43,187 shares), suggesting no significant shift in conviction. Therefore, a 'hold' recommendation is appropriate as this transaction does not provide new fundamental information to alter an investment thesis.

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan, Beneficial Ownership